Abstract
. However, imatinib has been unable to completely eliminate BCR-ABL-expressing leukaemic cells [2, 3] , and patients frequently present with cellular and clinical drug resistance [4] [5] [6] [7] [8] [9] [10] . We and others have shown that imatinib prolongs survival of mice with BCR-ABL-induced CML [11, 12] , but does not cure the disease [11] . Recently, three newly developed BCR-ABL kinase inhibitors, dasatinib [13] , AP23464 [14] and AMN107 [15] 
, have been shown to inhibit almost all imatinib-resistant BCR-ABL mutants in cell culture and animal studies; the exception is the BCR-ABL-T315I mutant, which is present in 15-20% of patients resistant to imatinib therapy. Besides its anti-BCR-ABL kinase activity, dasatinib is also a potent inhibitor of SRC family kinases, but the role of the anti-SRC activity of this compound in Ph
+ leukaemia therapy has not been studied [13] . [19] . The more superb therapeutic effect of dasatinib on B-ALL than on CML could be due to the activity of dasatinib against SRC kinases. As mentioned above, the pathways that regulate self-renewal of stem cells for haematologic malignancies involve the Bim-1 [38] and Wnt/␤-catenin [36] pathways, and SRC kinases may be involved in regulation of the ␤-catenin pathway [51] . In addition, v-SRC has been shown to activate ␤-catenin-
LEF/TCF (lymphoid enhancer factor/T-cell factor)-mediated transcription through the mitogen-activated protein kinase (MAPK) pathway [52]. A possible role of SRC kinases in self-renewal of Ph
+ leukaemia needs to be further studied. [33, 34, 53] . (Fig. 1B) (Fig. 1C) .
SRC kinase may impact B-ALL stem cell functions through activation of the downstream signalling molecule ␤-catenin

Activation of ␤-catenin in the Wnt signalling pathway has been shown to play a role in self-renewal of HSCs and proliferation of tumour cells
As mentioned above, this molecule is activated in granulocyte-macrophage progenitors of advanced phase CML patients and is involved in self-renewal ability of these cells in vitro [36]. The striking therapeutic effect of dasatinib, but not imatinib, on B-ALL [19] suggests that inhibition of SRC kinases not only played a key role in killing the highly proliferating leukaemic cells, but also may have an inhibitory effect on leukaemic stem cells, which would diminish the contribution of these stem cells to the disease. Therefore, we investigated whether SRC kinases are involved in activation of ␤-catenin in BCR-ABLexpressing cells. We observed that ␤-catenin is activated in the BCR-ABL-expressing mouse pre-B cell line (BaF/3) (Fig. 1A). To test whether activated SRC kinases directly activate ␤-catenin, we expressed v-SRC in BaF/3 cells. v-SRC activated ␤-catenin
To test whether inhibition of SRC kinases by dasatinib down-regulates ␤-catenin activation, we treated BCR-ABL-T315I-expressing pre-B leukaemic cells with dasatinib. ␤-catenin activation was inhibited by dasatinib at 100 nM, and this was associated with complete inhibition of SRC activation (Fig. 1D). These results link SRC kinases to ␤-catenin activation, implying that Src kinase may impact B-ALL stem cell functions through activation of the downstream signalling molecule ␤-catenin.
Activation of SRC kinases by BCR-ABL is independent of its kinase activity
BCR-ABL activates SRC kinases in myeloid cells, and SRC kinase inhibitors impair cellular transformation by BCR-ABL in cultured cells [54]. Stimulatory role of SRC kinases in transformation of lymphoid cells by BCR-ABL is demonstrated clearly using mice deficient for three SRC kinases LYN, HCK and FGR, and these three SRC kinases are shown to play a specific role in the induction of B-ALL not CML [11]. This lineage-specific function of SRC kinases indicates that SRC kinases are good therapeutic targets for B-ALL. The role of Lyn in BCR-ABL-induced
lymphoid leukaemia is also supported by a study using lymphoid blastic cells from CML patients [55] . [19] . [4, 54, 57] and dasatinib [13] . 
Lyn overexpression or inhibition of Lyn by the Src kinase inhibitor PP2 leads to an increase or decrease of Bcl-2 expression in LAMA84 and K562 cells [56], suggesting Bcl-2 may be a downstream signalling molecule of Lyn in BCR-ABL-positive cells. Because BCR-ABL activates SRC kinases, it is reasonable to think that inhibition of BCR-ABL kinase activity by imatinib would shut down SRC kinases that are downstream of BCR-ABL. The striking finding is that in B-lymphoid cells imatinib markedly inhibited BCR-ABL kinase activity but did not result in a decrease in SRC activation, indicating that while imatinib was very effective in inhibiting BCR-ABL phosphorylation, it was unable to affect BCR-ABLstimulated phosphorylation of SRC kinases
These observations indicate that activation of SRC kinases by BCR-ABL is independent upon its kinase activity, suggesting the necessity of targeting both BCR-ABL and SRC kinases in treating B-ALL. The inability of imatinib to inactivate SRC kinases may explain the relatively poor activity of this drug against Ph + B-ALL and acute lymphoid leukaemia.
Role of SRC kinases in the development of B-ALL
As mentioned above, the critical role of SRC kinases in the development of BCR-ABL-induced is first
Fig. 1 Downstream signalling molecules activated by SRC kinases. (A) SRC kinases activate ␤-catenin in BCR-ABLexpressing leukaemic cells. Protein lysates from parental and BCR-ABL-expressing BaF/3 pre-B cells were analysed by Western blotting using anti-␤-catenin and -␤-actin antibodies. (B) v-SRC activates ␤-catenin. Protein lysates from parental and v-SRC-expressing BaF/3 pre-B cells were analysed by Western blotting using anti-c-SRC, -␤-catenin, -␤-actin antibodies. (C) Lack of LYN, HCK and FGR causes reduction of ␤-catenin activation in BCR-ABL-expressing leukaemic cells. Protein lysates from BCR-ABL-transformed wild-type (WT) and Lyn
Inhibition BCR-ABL kinase activity and SRC kinase leads to long-term survival of B-ALL mice
Imatinib only has a weak therapeutic effect on B-ALL [19] , and this is likely due to the fact that SRC kinases are still active when BCR-ABL phosphorylation is inhibited by imatinib [19] . 
